NovaBay Reports Receiving of First Large NeutroPhase Order

NovaBay Pharmaceuticals, Inc.

, a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner China Pioneer Pharma Holdings, Limited (HK Stock Code:1345), a leading marketer of branded pharmaceutical products and medical devices in China, has placed its first order for NovaBay's NeutroPhase^® Skin and Wound Cleanser. NovaBay will be shipping NeutroPhase to China later this year to support Pioneer's launch of the product in early 2015 throughout mainland China. The order follows the clearance in early September of NeutroPhase for sale in China by China's Food and Drug Administration. “We believe that China will be a significant market for NeutroPhase because the product has the potential to bring a major improvement in medical care in China,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. NeutroPhase offers new options for managing both the chronic wounds of diabetes patients and for deadly flesh-eating disease (necrotizing fasciitis). China is now experiencing what experts call a ‘catastrophic' epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, approximately 100 million Chinese already suffer from this condition and from the side effects of diabetes, such as diabetic ulcers and other chronic wounds. NeutroPhase is ideally formulated for the management of these types of wounds and many others such as venous stasis ulcers and pressure ulcers that can seriously affect a patient's morbidity and mortality. NovaBay's FDA-cleared NeutroPhase has shown remarkable properties in the management of these categories of wounds. As John Crew, M.D., FACS states in the peer-reviewed International Journal of Burns and Trauma, “Patients showed a profound improvement and marked accelerated rates of wound healing using NeutroPhase with and without NPWT (negative pressure wound therapy). NeutroPhase was non-toxic to living tissues.” NeutroPhase contains a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that NeutroPhase not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties enable NeutroPhase to address acute infections and to help promote the healing of chronic wounds.